Novartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease - Seite 4

About Novartis
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com/.

Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews
For Novartis multimedia content, please visit https://www.novartis.com/news/media-library
For questions about the site or required registration, please contact [e-mail]

References

1. Saraf SL, et al. Paediatr Respir Rev. 2014;15(1):4-12.
2. Novartis AG. Sickle Cell Disease Around the World. Basel, Switzerland: 2019:1-6
3. Piel FB, et al. Lancet. 2013;381(9861);142-151
4. Stuart MJ, et al. Lancet. 2004;364(9442):1343-1360.
5. National Institutes of Health (NIH). Sickle cell disease. Bethesda, MD. U.S. National Library of Medicine. 2018:1-7.
6. Conran N, Franco-Penteado CF, Costa FF. Hemoglobin. 2009;33(1):1-16.
7. Ballas SK, et al. Blood. 2012;120(18):3647-3656.
8. Elmariah H, et al. Am J Hematol. 2014(5):530-535.
9. Steinberg M. New England Journal of Medicine. 1999;340(13):1021-1030.
   
   

# # #

Novartis Media Relations
E-mail: [e-mail]

Antonio Ligi Novartis External Communications [phone] (direct) [e-mail]   Jamie Bennett Novartis US External Communications [phone] [e-mail]

Kara Cournoyer Novartis Institutes for Biomedical Research [phone] (direct) [e-mail]   Katerina Kontzalis Global Health & CR Communications [phone] (direct) [e-mail]

Novartis Investor Relations
Central investor relations line: [phone]
E-mail: [e-mail]

Central		North America
Samir Shah	[phone]	Sloan Simpson	[phone]
Thomas Hungerbuehler	[phone]
Isabella Zinck	[phone]